Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,236 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,066
- Phase 1823
- Phase 1/Phase 2446
- Phase 3426
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis345
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama179
- Arizona141
- Florida141
- New York122
- Massachusetts120
- Texas119
- Illinois82
- Colorado77
Recruiting studies6,236 total
- NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT07520162RecruitingPhase 3
Tezepelumab for Nasal Polyps in Chinese Adults
This study tests whether tezepelumab, a new injectable medicine, can help reduce nasal polyps and improve symptoms like nasal congestion, loss of smell, and sleep problems. You would receive the study drug while continuing your current nasal steroid spray, and your doctors would track how your symptoms change.
BeijingAges 18 years+ - NCT06447597RecruitingPhase 2/Phase 3
Study of B007 for Generalized Myasthenia Gravis
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
BeijingAges 18–70 - NCT07332481RecruitingPhase 3
Testing enpatoran for lupus affecting the skin
This trial tests if a drug called enpatoran can help people with lupus that causes skin rashes, like discoid lupus or subacute cutaneous lupus. It may be for those with or without systemic lupus.
Los Angeles, CaliforniaAges 18–75 - NCT05020236RecruitingPhase 3
Elranatamab with daratumumab for previously treated myeloma
This trial studies elranatamab (alone and combined with daratumumab) in people with multiple myeloma who have already received other treatments, including lenalidomide. It aims to see how well these medicines control the cancer and what side effects people experience.
Clovis, CaliforniaAges 18 years+ - NCT07409246RecruitingPhase 1
Study of ABBV-438 for multiple myeloma patients
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
Duarte, CaliforniaAges 18 years+ - NCT07560813Recruiting
Nutrition and food support for pregnant people with diabetes
This study helps pregnant people with type 1 or type 2 diabetes who struggle to afford healthy food. You'll receive nutrition counseling and access to fresh food through a local program to help manage your blood sugar and have a healthier pregnancy.
Columbus, OhioAges 18 years+ - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT06540144Enrolling by invitationPhase 3
Extended rozanolixizumab treatment for children with myasthenia gravis
This study continues treatment for children who took part in an earlier trial (MG0006) for generalized myasthenia gravis. It tests 6-week cycles of a drug called rozanolixizumab to see if it continues to work well and stay safe.
BolognaAges 2 years+ - NCT05835310RecruitingPhase 3
IV anifrolumab for active lupus in children
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
Phoenix, ArizonaAges 5–17 - NCT07325292RecruitingPhase 3
Frexalimab injection vs IV for multiple sclerosis
This study tests if a new injection (frexalimab) works as well as the IV version for people with relapsing or certain types of secondary progressive multiple sclerosis. It could offer a more convenient way to receive this treatment at home.
Cullman, AlabamaAges 18–60 - NCT05748171RecruitingPhase 2
Testing inotuzumab for children with early ALL relapse
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
ViennaAges 1–17 - NCT07555938RecruitingPhase 3
New drug combination for previously treated multiple myeloma
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
Duarte, CaliforniaAges 18 years+ - NCT06047171RecruitingPhase 2
Testing ALE.F02 for new kidney inflammation from vasculitis
This trial tests a new medicine called ALE.F02 for people newly diagnosed with a type of kidney inflammation called rapidly progressive glomerulonephritis (RPGN) caused by ANCA vasculitis. The goal is to see if it can help rescue kidney function.
PragueAges 18 years+ - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17 - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Phoenix, ArizonaAges 12 years+ - NCT07609719RecruitingPhase 4
Switch to under-the-skin ocrelizumab for multiple sclerosis
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
GuaynaboAges 18–65 - NCT07763054Recruiting
Low-dose antifungal prevention for patients with low white blood cell counts
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
Hainan, HainanAges 18–75 - NCT06192563Recruiting
Dupilumab for severe eczema with limited skin rash
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
BolognaAges 6 months–17 years - NCT05704361RecruitingPhase 1
Study of an experimental drug for multiple sclerosis
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
Stanford, CaliforniaAges 18–65 - NCT07562022RecruitingPhase 3
SCTB35 Plus Lenalidomide for Resistant Follicular Lymphoma
This trial tests a new drug called SCTB35 combined with lenalidomide (a known cancer drug) in people whose follicular lymphoma (a type of blood cancer) has stopped responding to or come back after previous treatments. The combination may help shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–80 - NCT06622005RecruitingPhase 1
Combination treatment for multiple myeloma that has returned
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
Buffalo, New YorkAges 18 years+ - NCT06359041RecruitingPhase 1/Phase 2
CABA-201 cell therapy for generalized myasthenia gravis
This trial tests a new cell therapy called CABA-201 for people with generalized myasthenia gravis. It aims to reset the immune system to reduce muscle weakness and improve daily functioning.
Orange, CaliforniaAges 18–70 - NCT07224321RecruitingPhase 2
Inhaled insulin for youth with newly diagnosed type 1 diabetes
This study tests an inhaled insulin called Afrezza for teenagers and children who have just been diagnosed with type 1 diabetes. It aims to see if this new way of taking insulin can help manage blood sugar and fit into their lives.
Los Angeles, CaliforniaAges 6–17
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,236 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,675 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.